SEFA-6179 by NorthSea Therapeutics for Liver Diseases: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SEFA-6179 overview

SEFA-6179 is under development for the treatment of intestinal failure-associated liver disease (IFALD).  The drug candidate acts by targeting G protein coupled receptor 84 (GPR84), PPAR alpha and gamma receptors and is administered through oral route. It is being developed based on structurally engineered fatty acid (SEFA) technology. The therapeutic candidate is a fully synthetic medium chain fatty acid (MCFA) analogue.

NorthSea Therapeutics overview

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

For a complete picture of SEFA-6179’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.